Portola Pharmaceuticals, Inc.

Cor Therapeutics, Inc.

Millennium Pharmaceuticals Limited

Alexion Pharmaceuticals, Inc.

Eidos Therapeutics, Inc.

Global Blood Therapeutics, Inc.

Calcilytix Therapeutics, Inc.

Uma Sinha

Genmin Lu

Patrick Andre

David R Phillips

David Lawrence Wolf

Pamela B Conley

Robert M Scarborough

Bing-Yan Zhu

Stanley J Hollenbach

Anjali Pandey

Athiwat Hutchaleelaha

Xiaoming Zhang

Zhe Li

Charles K Marlowe

Alan M Laibelman

Satish Rao

Wolin Huang

Mukund Mehrotra

Jason R Harris

Mark Karbarz

Kobina N Dufu

Xin Geng

Keith Abe

Hilary Cannon

Ali Komeyli

Ananth Sridhar

Leena Prasad

Craig M Grant

The present disclosure provides tablet formulations including a triphenyl calcilytic compound for the treatment of autosomal dominant hypocalcemia (ADH), where the compound is represented by formula (I): a solvate, a hydrate, a pharmaceutically acceptable salt, or a combination thereof.

Formulations of triphenyl calcilytic compounds

Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects

Methods of treating TTR amyloidosis using AG10

The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Antidotes for factor Xa inhibitors and methods of using the same

Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.

The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same

This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.

Methods of treatment

Antidotes for factor XA inhibitors and methods of using the same

The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.

Combination therapy with a compound acting as a platelet ADP receptor inhibitor

Growing community of inventors

San Francisco, CA, United States of America

Uma Sinha